Cargando…

Influence of DPYD9A, DPYD6 and GSTP1 ile105val Genetic Polymorphisms on Capecitabine and Oxaliplatin (CAPOX) Associated Toxicities in Colorectal Cancer (CRC) Patients

AIM: CAPOX treatment in CRC patients was reported to cause several dose-limiting toxicities, and are found responsible for treatment interruption or even discontinuation. Therefore there is a critical need for identifying the predictive biomarkers for such toxicities to prevent them. The aim of our...

Descripción completa

Detalles Bibliográficos
Autores principales:	K, Ashok Varma, Jayanthi, M, Dubashi, Biswajit, Shewade, D G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	West Asia Organization for Cancer Prevention 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982684/ https://www.ncbi.nlm.nih.gov/pubmed/31653159 http://dx.doi.org/10.31557/APJCP.2019.20.10.3093

Ejemplares similares

Predictive value of clinical toxicities of chemotherapy with fluoropyrimidines and oxaliplatin in colorectal cancer by DPYD and GSTP1 gene polymorphisms
por: Deng, Xunwei, et al.
Publicado: (2020)

New advances in DPYD genotype and risk of severe toxicity under capecitabine
por: Etienne-Grimaldi, Marie-Christine, et al.
Publicado: (2017)

Allelic Frequency of DPYD Genetic Variants in Patients With Cancer in Spain: The PhotoDPYD Study
por: Miarons, Marta, et al.
Publicado: (2023)

A Novel DPYD Variant Associated With Severe Toxicity of Fluoropyrimidines: Role of Pre-emptive DPYD Genotype Screening
por: Tong, Chi C., et al.
Publicado: (2018)

GSTP1 Ile105Val Polymorphism and Prostate Cancer Risk: Evidence from a Meta-Analysis
por: Wei, Bingbing, et al.
Publicado: (2013)

Association of GSTP1 Ile105Val polymorphism with the risk of coronary heart disease: An updated meta-analysis
por: Song, Yadong, et al.
Publicado: (2021)

Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients
por: Stavraka, Chara, et al.
Publicado: (2019)

Simultaneous identification of GSTP1 Ile105→Val105 and Ala114→Val114 substitutions using an amplification refractory mutation systempolymerase chain reactionassay: studies in patients with asthma
por: Hemmingsen, Anja, et al.
Publicado: (2001)

Association between GSTP1 Ile105Val polymorphism and urinary system cancer risk: evidence from 51 studies
por: Zhang, Yixiang, et al.
Publicado: (2016)

Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase (DPYD) gene
por: García-González, Xandra, et al.
Publicado: (2018)

DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients
por: Del Re, Marzia, et al.
Publicado: (2019)

Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a DPYD variant and decreased dihydropyrimidine dehydrogenase enzyme activity
por: Ockeloen, Charlotte W, et al.
Publicado: (2021)

Frequency of the DPYD * 2A allele in the Czech population
por: Koudová, Monika, et al.
Publicado: (2014)

Association of GSTP1 Ile105Val Polymorphism and Risk of Head and Neck Cancers: A Meta-Analysis of 28 Case-Control Studies
por: Lang, Juntian, et al.
Publicado: (2012)

Associations between null mutations in GSTT1 and GSTM1, the GSTP1 Ile(105)Val polymorphism, and mortality in breast cancer survivors
por: Duggan, Catherine, et al.
Publicado: (2013)

An Evaluation of the Diagnostic Accuracy of a Panel of Variants in DPYD and a Single Variant in ENOSF1 for Predicting Common Capecitabine Related Toxicities
por: Palles, Claire, et al.
Publicado: (2021)

Revisiting the Clinical Importance of DPYD*9A (c.85T>C) Variant of Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients Treated with Fluoropyrimidine-Based Chemotherapy
por: Patel, Girijesh Kumar, et al.
Publicado: (2018)

The Association of Seminal Plasma Antioxidant Levels and Sperm Chromatin Status with Genetic Variants of GSTM1 and GSTP1 (Ile105Val and Ala114Val) in Infertile Men with Oligoasthenoteratozoospermia
por: Lakpour, Niknam, et al.
Publicado: (2013)

Evaluation of glutathione S-transferase P1 (GSTP1) Ile105Val polymorphism and susceptibility to type 2 diabetes mellitus, a meta-analysis
por: Saadat, Mostafa
Publicado: (2017)

Mutations at codon 974 of the DPYD gene are a rare event.
por: Ridge, S. A., et al.
Publicado: (1997)

Mutations at codon 974 of the DPYD gene are a rare event.
por: Diasio, R. B., et al.
Publicado: (1997)

DPYD and Fluorouracil-Based Chemotherapy: Mini Review and Case Report
por: Wigle, Theodore J., et al.
Publicado: (2019)

Ethnic Diversity of DPD Activity and the DPYD Gene: Review of the Literature
por: White, Cassandra, et al.
Publicado: (2021)

The Interaction between GSTT1, GSTM1, and GSTP1 Ile105Val Gene Polymorphisms and Environmental Risk Factors in Premalignant Gastric Lesions Risk
por: Negovan, Anca, et al.
Publicado: (2017)

GSTP1 Ile105Val polymorphism might be associated with the risk of radiation pneumonitis among lung cancer patients in Chinese population: A prospective study
por: Du, Lehui, et al.
Publicado: (2018)

Through translational prospective study, the GSTP1 Ile105Val polymorphism emerges as prognostic marker in de novo large B-cell lymphoma patients
por: Delamain, M T, et al.
Publicado: (2017)

GSTM1, GSTT1 and GSTP1 Ile105Val polymorphisms in outcomes of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation
por: Pincinato, Eder C., et al.
Publicado: (2019)

Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk
por: De Mattia, Elena, et al.
Publicado: (2022)

DPYD Exon 4 Deletion Associated with Fluoropyrimidine Toxicity and Importance of Copy Number Variation
por: Wigle, Theodore J., et al.
Publicado: (2023)

Implementation and clinical benefit of DPYD genotyping in a Danish cancer population
por: Paulsen, N.H., et al.
Publicado: (2023)

GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group
por: Kweekel, D M, et al.
Publicado: (2008)

From Six Gene Polymorphisms of the Antioxidant System, Only GPX Pro198Leu and GSTP1 Ile105Val Modulate the Risk of Acute Myeloid Leukemia
por: Bănescu, Claudia, et al.
Publicado: (2016)

Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity
por: Loganayagam, A, et al.
Publicado: (2013)

A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant
por: De Falco, Vincenzo, et al.
Publicado: (2019)

Poor association between dihydropyrimidine dehydrogenase ( DPYD ) genotype and fluoropyrimidine‐induced toxicity in an Asian population
por: Kanai, Masashi, et al.
Publicado: (2022)

Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia
por: Wu, Angela, et al.
Publicado: (2023)

Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD Variants
por: Lunenburg, Carin A. T. C., et al.
Publicado: (2018)

Near Miss or Standard of Care? DPYD Screening for Cancer Patients Receiving Fluorouracil
por: Winquist, Lauren E., et al.
Publicado: (2020)

Concordance of Blood-Based and Normal Tissue-Based Dihydropyrimidine Dehydrogenase (DPYD) Genotyping
por: Morelli, Cristina, et al.
Publicado: (2022)

Importance of Rare DPYD Genetic Polymorphisms for 5-Fluorouracil Therapy in the Japanese Population
por: Hishinuma, Eiji, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u7l86ptvki0l7o3acrgjkm56nh